Clinical Research Details

Clinical Research

An Open-Label Dose Escalation Study to Evaluate the Safety and Efficacy of AGTC-501 (rAAV2tYF-GRK1-RPGR) in Subjects with X-linked Retinitis Pigmentosa caused by RPGR-ORF15 mutations (20172166)

Study Description

Phase IIa/b trial for gene therapy in X-linked Retinitis Pigmentosa

Inclusion/Exclusion Criteria

not enrolling

Investigators


Sandeep Grover, M.D.
Ophthalmology